The research, led by Jun Min and Xiaoke Hu of the Yantai Institute of Coastal Zone Research at the Chinese Academy of Sciences, together with colleagues Yahui Zhang, Yanhong Xu, Suyun Fang, and Lingxue Xu, focused on a soil bacterium called Cupriavidus sp. CNP-8. This organism is a metabolic specialist with a taste for the unnatural: it can grow on a range of halogenated nitroaromatic compounds, using them as food. Earlier observations had shown that bacteria capable of degrading synthetic halo- and nitro-substituted aromatics often display chemotactic responses toward them, but the molecular machinery behind that attraction remained obscure. For decades, the assumption had been straightforward: somewhere on the bacterial surface or within the cell, a receptor protein must bind the pollutant directly, the way known chemoreceptors bind sugars or amino acids. The new work dismantles that assumption.

Bacterial chemotaxis depends on a family of proteins called methyl-accepting chemotaxis proteins, or MCPs. These are transmembrane sensors that monitor the chemical environment and relay signals to an internal signaling cascade, ultimately steering the rotation of the bacterium’s flagellar motor. When an MCP detects an attractive chemical gradient, it biases the cell’s swimming pattern so that the bacterium spends more time moving up the gradient toward the source. In the canonical model, the sensing happens through a ligand-binding domain that physically clutches the target molecule. The Yantai team asked whether the receptor responsible for detecting halogenated nitrophenols in CNP-8 followed this textbook design, and their answer reshapes how microbiologists may need to think about pollutant sensing in general.

The first step was genetic. The researchers systematically deleted candidate chemoreceptor genes from CNP-8 and tested whether the mutant bacteria lost their ability to swim toward halogenated nitrophenols, including 2-chloro-4-nitrophenol, 2-chloro-5-nitrophenol, 2,6-dichloro-4-nitrophenol, and 2,6-dibromo-4-nitrophenol. One gene stood out. When the researchers knocked out a gene they designated mcp4250, the bacterium’s chemotactic response toward both monohalogenated and dihalogenated nitrophenols collapsed. Restoring the gene through complementation brought the behavior back. This established that MCP4250, a member of the methyl-accepting chemotaxis protein family, is the receptor involved in the bacterium’s attraction to these synthetic pollutants. It was, notably, the first chemoreceptor ever implicated in chemotaxis toward halogenated nitroaromatic compounds.

Then came the surprise. If MCP4250 were a conventional pollutant receptor, its ligand-binding domain should clasp the nitrophenols themselves. The team purified the ligand-binding domain, which they call MCP4250LBD, and probed its binding behavior with isothermal titration calorimetry, a sensitive technique that measures the heat released or absorbed when two molecules interact, allowing precise quantification of binding affinity and stoichiometry. The result was unambiguous: MCP4250LBD did not bind to any of the halogenated nitrophenols. The receptor that mediates attraction to these pollutants cannot actually detect them directly. Instead, the calorimetry experiments revealed a completely different set of binding partners: intermediates of the tricarboxylic acid cycle, the universal metabolic engine that cells use to extract energy from food. The domain bound cis-aconitate, citrate, malate, isocitrate, and alpha-ketoglutarate, with cis-aconitate emerging as the tightest-binding ligand.

This finding points to a fundamentally different sensing strategy, one the authors describe as metabolic integration rather than direct substrate recognition. The logic works like this: when CNP-8 cells encounter and begin degrading halogenated nitrophenols, the catabolic process feeds carbon into the bacterium’s central metabolism, perturbing the pool of TCA cycle intermediates inside the cell. MCP4250, rather than sitting on the cell surface clutching pollutant molecules, appears to monitor these internal metabolic fluctuations. As the bacterium metabolizes the nitrophenols, changes in intracellular concentrations of compounds like cis-aconitate and citrate are registered by the receptor, and this information is converted into a swimming bias that steers the cell toward higher concentrations of the pollutant. In effect, the bacterium navigates toward the toxin by tasting the byproducts of its own digestion of that toxin, an indirect strategy that allows a receptor built around ordinary cellular chemistry to track molecules too foreign to be recognized directly.

The team went further, dissecting the receptor at the level of individual amino acids. Genetic deletion of the segment of the mcp4250 gene encoding the ligand-binding domain showed that this region plays an essential role in the chemotactic response, confirming that the TCA-intermediate binding they observed is not an incidental artifact but the functional heart of the sensing mechanism. They then used site-directed mutagenesis, systematically substituting specific amino acids within a predicted binding pocket of the domain, and repeated the isothermal titration calorimetry assays on each mutant. This allowed them to identify the key residues responsible for anchoring the TCA cycle intermediates, mapping the physical interface between the receptor and its metabolic ligands. Such residue-level characterization provides a structural framework for understanding how a chemoreceptor can be tuned to read intracellular metabolic state rather than extracellular substrate.

Evolution adds another layer of intrigue. When the researchers placed MCP4250 into a phylogenetic tree alongside other functionally characterized chemoreceptors, the protein did not cluster with any of them. Its evolutionary origin appears to be unique, distinct from the established families of receptors that sense sugars, amino acids, or organic acids through conventional mechanisms. This deep evolutionary separation suggests that the metabolic-integration strategy may have arisen independently, an example of convergent innovation in which bacteria facing xenobiotic pollutants found a workaround to the problem of sensing molecules their receptor proteins could not evolve to bind. It also hints that other pollutant-degrading microbes scattered across contaminated environments may harbor their own versions of this trick, waiting to be discovered.

The practical implications reach well beyond basic microbiology. Bioremediation, the use of living organisms to clean up contaminated sites, depends heavily on bacteria that can locate and degrade pollutants efficiently. Chemotaxis is a critical ingredient in that efficiency: a degrading bacterium that swims toward its target compound will reach and process contamination far faster than one that waits passively for diffusion to deliver substrate. Understanding that MCP4250 and receptors like it steer bacteria by reading metabolic flux rather than pollutant concentration directly could guide the engineering of enhanced bioremediation strains, for example by tuning receptor sensitivity to metabolic intermediates or by introducing such receptors into organisms that already possess powerful degradation pathways but lack the navigational instinct. The work was supported by the National Natural Science Foundation of China and the Youth Innovation Promotion Association Program of the Chinese Academy of Sciences.

Scientifically, the study broadens the conceptual catalog of how chemoreceptors can operate. Textbook chemotaxis has always been a story of direct molecular recognition, a lock-and-key encounter between sensor and signal. MCP4250 demonstrates that bacteria can also solve the sensing problem by proxy, converting the metabolic consequences of consuming a compound into directional movement toward it. As the first biochemically identified chemoreceptor mediating chemotaxis toward halogenated nitroaromatic compounds, it extends the known diversity of chemoreceptor function and offers a concrete molecular example of what researchers have long suspected from behavioral observations: that bacteria can sense synthetic pollutants even when no receptor has evolved to see them. For a class of chemicals that has troubled environmental engineers for decades, the microscopic hunters that chase them down have finally revealed part of their secret, and it is a secret written not in the language of pollutant recognition but in the ancient vocabulary of cellular metabolism.

Subject of Research: Identification of the chemoreceptor MCP4250 that mediates bacterial chemotaxis toward halogenated nitrophenols through sensing of TCA cycle intermediates

Article Title: MCP4250, a novel chemoreceptor, mediates chemotaxis toward halogenated nitrophenols in Cupriavidus sp. CNP-8

Article References: Min, J., Zhang, Y., Xu, Y., Fang, S., Xu, L., & Hu, X. (2026). MCP4250, a novel chemoreceptor, mediates chemotaxis toward halogenated nitrophenols in Cupriavidus sp. CNP-8. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14061-z

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14061-z

Keywords: chemotaxis, chemoreceptor, MCP4250, Cupriavidus, halogenated nitrophenols, bioremediation, methyl-accepting chemotaxis protein, TCA cycle, ligand binding, isothermal titration calorimetry, xenobiotic pollutants, bacterial sensing

The research, led by Cassandra E. Gheorghe and Juliette Montet of the NutriNeuro laboratory at the University of Bordeaux, together with colleagues at INRAE and clinical partners in the Bordeaux region, set out to test whether disruptions in mitochondrial energy metabolism might help explain the comorbidity between obesity and neuropsychiatric symptoms. While chronic low-grade inflammation has been the dominant explanation in the literature for years, the authors argue that additional immunometabolic alterations, particularly those affecting the tricarboxylic acid (TCA) cycle, may play a significant and previously underappreciated role.

The TCA cycle, also known as the Krebs cycle or citric acid cycle, is a sequence of biochemical reactions that takes place inside mitochondria, the organelles often described as cellular power plants. The cycle oxidizes nutrients derived from carbohydrates, fats, and proteins, generating intermediate metabolites such as citrate, succinate, and malate, which feed the electron transport chain that ultimately produces adenosine triphosphate, the universal energy currency of cells. Because the brain is among the most energetically demanding organs in the body, even subtle perturbations in this machinery could, in principle, influence mood, motivation, and the subjective sense of vitality.

To investigate this possibility, the research team adopted a dual approach that combined human clinical data with animal experiments, a design that strengthens the translational relevance of the findings. On the clinical side, they recruited 83 adults with obesity, defined as a body mass index above 30 kilograms per square meter, and measured the circulating levels of TCA cycle metabolites in their blood plasma. Crucially, they did not stop at metabolic measurements. Each participant also completed validated psychometric assessments: the Montgomery-Asberg Depression Rating Scale for depressive symptoms, the state form of the State-Trait Anxiety Inventory for anxiety, and the Multidimensional Fatigue Inventory for fatigue.

The results revealed a striking pattern. Lower levels of circulating TCA cycle metabolites were associated with more severe neuropsychiatric symptoms in the obese participants, with the strongest and most consistent associations observed for fatigue and reduced motivation. In other words, the individuals whose blood showed the most pronounced depletion of these key metabolic intermediates were also the ones reporting the greatest exhaustion and diminished drive. Interestingly, the associations differed across symptom dimensions, suggesting that distinct aspects of the TCA cycle may map onto different neuropsychiatric phenotypes rather than a single undifferentiated state of psychological distress.

Correlation in humans, however, is only half the story. To probe whether these metabolic shifts have a causal or mechanistic connection to behavior, the team turned to a preclinical model. Male C57BL/6J mice were chronically exposed to a high-fat diet, a standard experimental paradigm for inducing obesity and its metabolic consequences. The researchers then assessed depressive-like behavior using the sucrose preference test, which measures anhedonia, the reduced ability to experience pleasure, and the forced swim test, a widely used index of behavioral despair. Anxiety-like behavior was evaluated with the elevated plus-maze, which exploits the natural conflict between a rodent’s curiosity and its aversion to open, exposed spaces.

Alongside these behavioral measures, the team quantified TCA cycle metabolite levels not only in the plasma but also in three discrete brain regions: the striatum, the hippocampus, and the frontal cortex. This regional analysis proved to be one of the most compelling aspects of the study. The preclinical data identified region-specific associations between brain TCA cycle metabolite levels and behavioral outcomes, and these associations appeared to be modulated by exposure to the high-fat diet. Each of the three regions examined plays a distinct role in emotional and motivational processing. The hippocampus is central to stress regulation and is consistently implicated in depression, the frontal cortex governs executive control and mood regulation, and the striatum is a hub of the reward circuitry that underlies motivation and pleasure seeking.

The finding that metabolic signatures in these specific circuits correlate with specific behavioral outputs lends biological plausibility to the human data. A metabolite profile in the striatum that tracks with anhedonia-like behavior, for example, would align neatly with the clinical observation that reduced motivation was among the symptoms most tightly linked to altered circulating metabolites. Although the study, by design, cannot definitively establish causation in humans, the convergence of the clinical and preclinical arms provides what the authors describe as novel evidence linking TCA cycle dysregulation to neuropsychiatric comorbidities in obesity, and it highlights specific metabolites as potential targets of interest for future research.

The implications of this work extend in several directions. First, it reframes obesity-related neuropsychiatric symptoms not merely as psychological reactions to weight, stigma, or social difficulties, but as phenomena with a measurable biochemical substrate rooted in mitochondrial metabolism. Second, it suggests that the long-standing focus on inflammation, while valuable, may capture only part of the immunometabolic picture. Mitochondrial function and inflammatory signaling are deeply intertwined, and metabolites of the TCA cycle themselves act as signaling molecules that can regulate immune cell behavior. Disruptions in the cycle could therefore feed back into the inflammatory processes already implicated in mood disorders, creating a self-reinforcing loop.

Third, the study opens the door to potential biomarker development. If specific circulating TCA cycle metabolites reliably track fatigue and motivational deficits in people with obesity, they could eventually serve as objective markers to identify patients at heightened neuropsychiatric risk, stratify them for targeted interventions, and monitor treatment response. Nutritional, pharmacological, or lifestyle strategies aimed at restoring mitochondrial metabolic function might then be evaluated in a more precise and personalized manner. The work was supported by the French National Research Institute for Agriculture, Food and Environment and by international funding programs dedicated to nutrition and health biomarkers, reflecting a growing institutional commitment to understanding how metabolism shapes mental health.

Important caveats remain. The clinical cohort was modest in size, and cross-sectional associations cannot determine whether reduced TCA cycle metabolite levels precede the neuropsychiatric symptoms or result from them. Fatigue and low motivation can themselves alter eating patterns, physical activity, and sleep, all of which influence mitochondrial metabolism. The preclinical experiments, while informative, used male mice only, leaving open questions about sex differences that are highly relevant given the epidemiology of both obesity and depression. Moreover, the human measurements were restricted to blood, so the extent to which circulating metabolite levels faithfully reflect what is happening inside the brain remains an active area of investigation, even though the animal data on brain-region-specific metabolite profiles provide valuable supporting evidence.

Nevertheless, the study represents a meaningful step forward in a field that has struggled to explain why so many individuals with obesity experience depression, anxiety, and exhaustion that cannot be fully accounted for by inflammation or psychosocial factors. By shining a light on the tricarboxylic acid cycle, the Bordeaux team has connected two research territories that rarely speak to each other: classical mitochondrial biochemistry and modern neuropsychiatric epidemiology. The metabolites they identified as being of potential interest now become candidates for longitudinal studies, intervention trials, and mechanistic follow-up work in both rodents and humans.

As the global prevalence of obesity continues to climb, and with it the burden of obesity-related mental health problems, research of this kind underscores a simple but powerful idea: the health of the mind may depend, in part, on the metabolic health of the cell. The mitochondria that power our muscles and organs also power our brains, and when their core metabolic machinery falters under the chronic metabolic stress of obesity, the consequences may be felt not only on the scale or in blood panels, but in mood, motivation, and the everyday energy needed to live a full life. The next chapter of this research will determine whether restoring the cycle can restore the spirit.

Subject of Research: TCA cycle metabolite disruptions and neuropsychiatric symptoms in obesity

Article Title: Translational evidence of tricarboxylic acid cycle disruptions in obesity: relevance to neuropsychiatric symptoms

Article References: Gheorghe, C. E., Montet, J., Vancassel, S., Amadieu, C., Leyrolle, Q., Dexpert, S., Beau, C., Forestier, D., Ledaguenel, P., Magne, E., Castanon, N., & Capuron, L. (2026). Translational evidence of tricarboxylic acid cycle disruptions in obesity: relevance to neuropsychiatric symptoms. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04476-7

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04476-7

Keywords: obesity, TCA cycle, mitochondria, depression, anxiety, fatigue, metabolites, neuropsychiatry, high-fat diet, immunometabolism, Translational Psychiatry, motivation

Retinal organoids, the three-dimensional tissues coaxed from stem cells that self-organize into layered, light-sensitive structures, have become one of the most celebrated tools in modern vision science. They allow researchers to study retinal development and inherited blindness without experimenting on animals, and they can be produced in large batches from a single starting culture. But most assessments of how faithfully organoids replicate the native retina have relied on RNA sequencing and proteomics, techniques that measure molecular blueprints rather than the actual chemistry of life. Genes can be switched on without the corresponding metabolic machinery running at full tilt, and proteins can be present without the small molecules they process flowing through pathways at realistic rates.

To close that gap, the team led by first author Pragati Gupta turned to untargeted metabolomics, a technique that captures the small molecules, sugars, amino acids, and lipids that represent the working currency of cellular metabolism. Using gas chromatography coupled to mass spectrometry, they compared the intracellular metabolite profiles of mouse retinal organoids at day 28 of differentiation with retinas dissected from three-day-old C57BL/6 mice. The choice of comparison points was deliberate: previous transcriptomic work had shown that day-28 organoids most closely resemble early postnatal retinal development, making the P3 retina the fairest developmental benchmark available.

The results were striking in their overall overlap. Of 166 annotated compounds detected across the study, 148 were shared between organoids and native retina, spanning amino acids and their derivatives, lipids and fatty acids, carbohydrates and sugar alcohols, and organic acids. Crucially, the conserved metabolites included the chemical heavyweights of retinal function: glutamate and gamma-aminobutyric acid, the central mediators of retinal neurotransmission; taurine, one of the most abundant metabolites in the vertebrate retina and essential for photoreceptor survival; and the TCA cycle intermediates citrate, succinate, fumarate, and malate that power the cell’s energy factories. The organoids, in other words, had built a genuinely retina-like biochemical identity rather than becoming some metabolically generic blob of tissue.

But the devil, as always, was in the differences. When the researchers applied stringent statistical thresholds, requiring a false discovery rate below 0.05 and a fold change of at least tenfold in either direction, a pattern of selective metabolic immaturity emerged. Several metabolites central to central carbon metabolism were abundant in native retina but fell below detection in organoids, including glucose-6-phosphate, a gateway metabolite of glycolysis; ribulose-5-phosphate, a signature intermediate of the pentose phosphate pathway; glycerol-3-phosphate and dihydroxyacetone phosphate, which link sugar metabolism to lipid synthesis; and phosphoethanolamine and myo-inositol, both tied to membrane phospholipid metabolism. TCA cycle-associated compounds including citric, fumaric, and oxalic acid also showed altered abundance between the two tissues.

Pathway enrichment analysis sharpened the picture further, identifying significant alterations in alanine, aspartate, and glutamate metabolism, along with changes in arginine biosynthesis, glycine, serine, and threonine metabolism, taurine and hypotaurine metabolism, and starch and sucrose metabolism. Multivariate statistics told the same story from a different angle. Principal component analysis and partial least squares discriminant analysis both separated organoids from native retina cleanly, with metabolites such as pantothenic acid, erythritol, phosphate, and glycerol-3-phosphate ranking among the strongest drivers of the distinction. Metabolites including urea, erythritol, phosphoethanolamine, and pyroglutamic acid pointed toward the native retina cluster, while fructofuranose, galactopyranose, and modified galactose derivatives pointed toward the organoids.

The team also tracked what the growing organoids ate and excreted, by analyzing the conditioned culture media collected longitudinally between day 8 and day 28 of differentiation. Here, the data revealed clear stage-dependent remodeling: early, intermediate, and late media samples each formed distinct clusters in multivariate space, with amino acid-associated and carbohydrate-associated metabolites showing the most pronounced temporal shifts. Notably, extracellular glutamate and glycine changed in abundance as the organoids matured, a finding consistent with earlier reports that developing retinal tissue actively consumes glutamate and aspartate. This supports an emerging concept in vision science of the retina as a metabolic ecosystem, in which photoreceptors, Müller glia, and the retinal pigment epithelium exchange lactate, nutrients, and antioxidants in a tightly choreographed economy.

Why does this matter beyond the laboratory bench? The retina’s extraordinary metabolic demands make it uniquely vulnerable to metabolic failure, and defects in energy metabolism are increasingly implicated in inherited retinal degenerations, diabetic retinopathy, and age-related macular degeneration. If organoids are to serve as faithful models of these diseases, or as testing grounds for gene therapies and cell transplants, their metabolic fidelity becomes a critical quality metric. The new findings suggest that current culture conditions produce organoids with the right metabolic vocabulary but an incomplete fluency: the core retinal metabolites are present, yet the energy-generating and biosynthetic pathways that support mature photoreceptor function have not fully caught up with the native tissue.

The authors are careful to frame their conclusions within the study’s limitations. Metabolomics by gas chromatography measures relative abundance rather than metabolic flux, so a metabolite absent from the organoid signal is not necessarily absent from the organoid itself; it may simply fall below the detection threshold or be lost during extraction and derivatization. The technique is also relatively blind to complex lipids, retinoids, and low-abundance signaling molecules, precisely the classes that matter for photoreceptor outer segments. The comparison captures a single developmental snapshot rather than a longitudinal trajectory, and some differences may reflect developmental asynchrony between a dish and a living eye rather than intrinsic organoid deficiencies. The organoids also lack the retinal pigment epithelium interaction and vascular nutrient exchange that shape retinal metabolism in vivo, and the conditioned media changes may partly reflect stage-specific culture supplements rather than biology alone.

Even so, the study delivers a practical roadmap. The specific metabolic gaps it identifies, in glycolysis, the pentose phosphate pathway, phospholipid metabolism, and amino acid neurotransmitter cycling, point directly to candidate interventions: adjusted nutrient compositions, improved oxygenation, co-culture with retinal pigment epithelium, and lipid or antioxidant supplementation of the kind already shown to improve photoreceptor outer segment development in earlier organoid studies. The authors also emphasize that their mouse organoid system, which matures in roughly 28 days compared with around 200 days for human retinal organoids, offers a fast, cost-effective platform aligned with the 3R principles of replacing, reducing, and refining animal use. Future work combining metabolomics with isotope tracing and functional assays should reveal whether these metabolic differences represent delayed maturation that culture optimization can fix, or a more fundamental ceiling of the dish-bound retina. Either way, the message is clear: to build a better retina in a dish, scientists must now feed it not just growth factors, but the right chemistry.

Subject of Research: Metabolomic comparison of stem cell-derived mouse retinal organoids and native mouse retina

Article Title: Metabolic profiling of retinal organoids reveals conserved core metabolites and alterations in glycolytic and amino acid metabolism

Article References: Gupta, P., Wiesner, C., Ziemssen, F., Klevering, J., Kulkarini, P., & Hosseinzadeh, Z. (2026). Metabolic profiling of retinal organoids reveals conserved core metabolites and alterations in glycolytic and amino acid metabolism. Metabolomics, 22(6), Article 171. https://doi.org/10.1007/s11306-026-02523-4

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02523-4

Keywords: retinal organoids, metabolomics, mouse retina, GC-MS, glycolysis, TCA cycle, amino acid metabolism, photoreceptors, taurine, glutamate, pentose phosphate pathway, stem cell models

The research, led by Anna C. Sanford of Tulane University School of Medicine together with Nell G. Bond, John S. Schieffelin, and colleagues, drew on an ongoing cohort study of Ebola virus disease survivors and their household contacts in Sierra Leone. The team collected plasma samples between March 2016 and April 2019 and applied untargeted metabolomics—liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS)—to survey hundreds of small molecules circulating in the blood. Their comparison groups were carefully constructed: 37 survivors with post-Ebola syndrome, split between those with musculoskeletal or gastrointestinal sequelae (18) and those with cardiopulmonary sequelae (19); 20 asymptomatic survivors who tested positive for Ebola virus glycoprotein IgG antibodies; and 20 asymptomatic household contacts who lacked these antibodies, matched as closely as possible to the survivors in age, sex, body mass index, and sample collection date.

The analytical pipeline was deliberately conservative. Peak intensities were normalized to the median and log-transformed, and variables with high relative standard deviation or near-constant values were filtered out before testing. Metabolites were considered significantly different only if they showed a fold change greater than 2.0 or less than 0.5—equivalent to an absolute log2 fold change above 1—combined with an adjusted p-value below 0.05 using the Benjamini-Hochberg false discovery rate correction. Of the 544 metabolites identified in the plasma samples, 34 met these stringent criteria when survivors with post-Ebola syndrome were compared with asymptomatic survivors. Twenty-six of these metabolites were significantly decreased in the PES group, while eight were increased. Importantly, logistic regression showed that age, sex, body mass index, and sample collection date did not predict group membership, meaning the metabolic differences could not be explained by these demographic factors.

The pattern of change was strikingly one-directional. Pathway analysis in MetaboAnalyst 6.0 revealed that the most heavily impacted downregulated pathways involved amino acid metabolism—including the taurine and hypotaurine pathways and the tyrosine, cysteine, and methionine pathways—alongside nucleotide metabolism, the tricarboxylic acid (TCA) cycle, glycolysis, and pyruvate metabolism. In other words, survivors with post-Ebola syndrome showed broad suppression of the central biochemical machinery that cells use to generate energy and build proteins and nucleic acids. A smaller set of pathways was significantly upregulated or showed mixed changes, including starch and sucrose metabolism, tryptophan metabolism, arginine and proline metabolism, nicotinate and nicotinamide metabolism, and pentose and glucuronate interconversions.

Because so many TCA cycle metabolites were affected, the researchers performed a network analysis to visualize how these compounds relate to one another. Spearman’s rank correlation analysis across the PES group revealed significant interconnections among metabolites in the TCA cycle, amino acid, fatty acid, and nucleotide metabolism pathways, and the network of TCA metabolites was visualized in Cytoscape, with node size reflecting the number of significant connections and line thickness reflecting the strength of the correlation. Notably, none of the demographic variables correlated with any metabolite in the PES group, reinforcing that the metabolic signature was independent of body composition, age, or sex. Multivariate approaches added further support: principal components analysis and partial least squares discriminant analysis (PLS-DA) separated survivors with post-Ebola syndrome from asymptomatic survivors, with the best two-component PLS-DA model achieving an accuracy of 0.86, an R2 of 0.66, and a Q2 of 0.45. Metabolites tied to the TCA cycle, short-chain fatty acid metabolism, and glucose carried the greatest weight in the model.

The team then asked whether a small panel of metabolites could serve as a diagnostic biomarker for post-Ebola syndrome. Using a discovery cohort of 39 randomly selected survivors—roughly two-thirds of the group—they trained both PLS-DA and Random Forest models, running one hundred iterations of Monte-Carlo cross-validation. The top ten most important metabolites were the same in both models: acrylate, glucose, acetate, 3-hydroxy-3-methylglutarate, malate, 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline, succinate, methylmalonate, threonate-1,4-lactone, and propanoate. When this fixed ten-metabolite panel was applied to an independent validation cohort of the remaining 18 survivors, which the discovery model had never seen, both models again achieved areas under the receiver operating characteristic curve above 0.8, with predictive accuracies of 0.799 for PLS-DA and 0.796 for Random Forest. The convergence of two independent machine-learning approaches on the same metabolite panel, and its successful validation on held-out data, strengthens the case that these molecules genuinely track the syndrome rather than reflecting statistical noise.

What might these metabolic shifts mean biologically? The authors point to converging evidence from other viral diseases. In cells stimulated with Ebola virus-like particles, fatty acid and amino acid metabolism are known to be reprogrammed, and fatal Ebola virus disease has previously been associated with depleted plasma free amino acids. In people living with HIV, altered amino acid metabolism and signs of mitochondrial disruption—including TCA cycle dysfunction—have been documented, and impaired mitochondrial function is a recognized hallmark of T-cell exhaustion in chronic infections such as HIV, hepatitis B, and lymphocytic choriomeningitis virus infection. The TCA cycle changes observed in survivors with post-Ebola syndrome are associated with diminished CD8+ T-cell activity in those chronic infection settings, raising the possibility that similar immunometabolic alterations persist in Ebola survivors who develop long-term sequelae. Prior work by other groups has shown that more survivors with PES mount Ebola-specific CD8+ T-cell responses than asymptomatic survivors, and metabolism is known to mediate immune cell differentiation and function, making the connection biologically plausible even though plasma measurements cannot be directly mapped onto cellular processes.

The short-chain fatty acid findings add another intriguing dimension. Acetate was increased while propanoate was decreased in the PES group, and the authors suggest that this pattern could reflect dysregulation of the gut microbiome. Reduced populations of short-chain fatty acid-producing symbionts have been reported in people with Long COVID, and short-chain fatty acids generally encourage anti-inflammatory immune responses while also modulating CD8+ T-cell activity. If the gut microbial community of Ebola survivors with post-Ebola syndrome has shifted away from these protective metabolite producers, it could provide a mechanistic bridge between infection, microbial ecology, and chronic immune dysfunction. The authors are careful, however, to note that any suggestion of viral persistence as a driver of these changes remains purely hypothetical with the current data.

The study has clear limitations that the authors acknowledge candidly. The sample size is modest, and the focus on two specific sequelae groups—musculoskeletal/gastrointestinal and cardiopulmonary—may limit generalizability to the broader spectrum of post-Ebola syndrome. No significant differences emerged when survivors with PES were compared with asymptomatic household contacts, which the authors attribute to limited statistical power, trends that did not reach significance, or possibly unique metabolic changes in asymptomatic survivors themselves. There were also no significant metabolite differences between the musculoskeletal/gastrointestinal and cardiopulmonary subgroups. Concurrent laboratory measurements such as inflammatory markers were unavailable for correlation, no acute-phase samples exist to distinguish persistent changes from those dating to the original illness, and longitudinal samples are lacking. Shared analytical features among some metabolites also limit precision, and the authors call for targeted metabolomics to resolve these ambiguities. Despite these caveats, the work establishes for the first time that Ebola survivors with post-Ebola syndrome carry a distinct and largely downregulated metabolic profile centered on energy metabolism, amino acids, nucleotides, and microbially derived short-chain fatty acids. The team plans mechanistic studies to determine how these changes arise and how they relate to immune function, and hopes to compare findings directly with post-viral syndromes following other infections such as SARS-CoV-2. More broadly, the study demonstrates the power of metabolomics to illuminate the biology of post-viral illness—a field where molecular explanations have long been sought and rarely found.

Subject of Research: Metabolic biomarkers of post-Ebola syndrome in Ebola virus disease survivors

Article Title: Metabolic basis of post-infectious sequelae after Ebola virus disease

Article References: Sanford, A. C., Bond, N. G., Ficenec, S., Osterman, C., Farkas, P., Engel, E., Gunn, B., Grant, D. S., Samuels, R., Zwezdaryk, K. J., & Schieffelin, J. S. (2026). Metabolic basis of post-infectious sequelae after Ebola virus disease. Metabolomics, 22(6), Article 170. https://doi.org/10.1007/s11306-026-02544-z

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02544-z

Keywords: Ebola virus disease, post-Ebola syndrome, metabolomics, TCA cycle, short-chain fatty acids, amino acid metabolism, biomarkers, Sierra Leone, T-cell exhaustion, gut microbiome, LC-MS/MS, post-viral sequelae

The research team set out with a deceptively simple question: how much of the flavor difference between bolete species is written in their chemistry? To answer it, they analyzed five bolete species using a battery of complementary analytical techniques. Taste-related metabolites — amino acids and organic acids — were profiled with a targeted metabolomics strategy based on ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry, known as UPLC-ESI-MS/MS. Aroma compounds were captured through widely targeted volatilomics using headspace solid-phase microextraction gas chromatography-mass spectrometry, or HS-SPME-GC-MS, a technique that allows volatile molecules floating above the mushroom flesh to be trapped on a fiber and then separated and identified with high sensitivity. Infrared spectra were recorded with attenuated total reflectance Fourier-transform infrared spectroscopy, ATR-FTIR for short, which measures how the sample’s molecular bonds absorb infrared light and produces a chemical fingerprint of the whole tissue.

The scale of the resulting dataset is striking. Across the five species, the researchers identified 68 amino acid metabolites, 57 organic acids, and a remarkable 773 volatile compounds. That sheer volume of chemical information is precisely why the team turned to chemometrics — statistical modeling methods designed to extract meaningful patterns from complex multivariate data. Using orthogonal partial least squares discriminant analysis, abbreviated OPLS-DA, together with variable importance in projection scores and two flavor-dilution metrics known as taste activity value and relative odor activity value, the researchers sifted through hundreds of candidates to find the compounds that actually drive the sensory differences between species rather than merely varying at random.

The screening converged on a compact set of chemical culprits. On the taste side, five key differential flavor-active compounds emerged: fumaric acid, glycine, arginine, aspartic acid, and lysine. These molecules are far from arbitrary choices. Aspartic acid and glycine are classic contributors to the savory umami and sweet notes prized in edible fungi, while arginine and lysine are essential and semi-essential amino acids that modulate overall taste balance. Fumaric acid, an intermediate of cellular energy metabolism, contributes sourness and acidity. Their differential abundance across species means that the fundamental taste architecture of a bolete is largely set by which of these molecules dominates its flesh.

The aroma story proved even more intricate. Six key aroma-active compounds were pinpointed: a furanone derivative identified as 3(2H)-furanone, dihydro-2-methyl-; three substituted pyrazines — 2-ethyl-3,5-dimethylpyrazine, 2,3-diethyl-5-methylpyrazine, and a third pyrazine variant; the ethyl ester of 3-methylbutanoic acid; benzeneacetaldehyde; and the green, fatty-smelling aldehyde (Z,Z)-3,6-nonadienal. Pyrazines are notorious for imparting roasted, nutty, and earthy notes, which helps explain the deep, forest-floor character that gourmets associate with premium porcini. The unsaturated aldehyde nonadienal, meanwhile, evokes fresh cucumber and green aromas at vanishingly low concentrations, and benzeneacetaldehyde carries a honeyed, floral sweetness. Together, this six-molecule ensemble functions as the olfactory signature that distinguishes one bolete species from another.

To understand where these differences come from, the team performed metabolic pathway analysis, which maps identified metabolites onto known biochemical networks. The analysis pointed to two central pathways as the engines of flavor divergence: the tricarboxylic acid cycle, or TCA cycle, and the urea cycle. The TCA cycle is the cell’s central metabolic hub, and its intermediates include organic acids such as fumaric acid that directly shape sourness and acidity. The urea cycle governs nitrogen metabolism and the interconversion of amino acids such as arginine. Differences in how actively these pathways run in each species — likely shaped by each fungus’s genetics, ecology, and growing conditions — cascade upward into the taste and aroma profiles that mushroom hunters and chefs perceive on the plate.

Perhaps the most futuristic element of the study is its attempt to connect aroma chemistry to human perception at the receptor level. Using molecular docking, a computational technique that predicts how small molecules fit into the binding pockets of proteins, the researchers tested whether the key aroma compounds could interact with olfactory receptors. The results showed that the key aroma compounds exhibited strong binding affinity to the olfactory receptor OR1A1, a human receptor known to respond to a range of food-relevant odorants. This suggests that the compounds flagged by the statistical screens are not just chemically abundant but are also plausibly capable of triggering human smell perception, strengthening the case that they are genuine drivers of the bolete aroma experience.

Beyond explaining flavor, the study delivers a practical tool with immediate commercial implications. ATR-FTIR spectroscopy is fast, inexpensive, and requires minimal sample preparation compared with the chromatographic methods used to build the reference dataset. The researchers exploited this by training a deep learning model — a hybrid convolutional neural network combined with a long short-term memory network, or CNN-LSTM — to predict key flavor component concentrations directly from infrared spectra. The hybrid architecture is well suited to the task: the convolutional layers extract local spectral features, while the LSTM layers capture sequential dependencies across the spectrum. The model achieved accurate and stable quantitative prediction, with coefficients of determination of at least 0.95 and relative predictive deviation values exceeding 4, thresholds generally regarded as excellent for analytical prediction models.

The implications ripple outward from the laboratory. Because the CNN-LSTM model can estimate key flavor components rapidly and reliably, the approach could allow buyers and regulators to grade bolete lots by predicted flavor rather than by appearance alone, and to detect species substitution — a persistent problem in the wild mushroom trade, where visually similar species command wildly different prices. The same spectroscopic-plus-machine-learning pipeline could in principle be adapted to other prized foods, from truffles to fermented teas, wherever flavor quality currently resists objective measurement. The study’s authors note that the work establishes both the chemical basis of flavor divergence among bolete species and a reliable, rapid detection method for flavor evaluation and species identification.

There is also a broader scientific payoff. By tying flavor differences to specific metabolic pathways, the study provides a framework for understanding how fungal metabolism translates into human sensory experience — a question that sits at the intersection of biochemistry, ecology, and food science. As wild-harvested mushrooms face pressure from climate change and habitat loss, knowing which species harbor the richest flavor chemistry, and being able to verify that chemistry quickly, may prove essential for both conservation-minded foraging and the economic survival of the communities that depend on the bolete harvest. What was once the exclusive judgment of the trained palate can now, it seems, be read in a spectrum.

Subject of Research: Chemical basis of flavor differences among bolete mushroom species analyzed by metabolomics, volatilomics, spectroscopy, and machine learning

Article Title: Effect of species on the flavor profile of boletes: insights from GC-MS, LC-MS, ATR-FTIR spectroscopy and chemometrics

Article References: Zhong, C., Li, J.-Q., & Wang, Y.-Z. (2026). Effect of species on the flavor profile of boletes: insights from GC-MS, LC-MS, ATR-FTIR spectroscopy and chemometrics. npj Science of Food. https://doi.org/10.1038/s41538-026-01187-7

Image Credits: AI Generated

DOI: 10.1038/s41538-026-01187-7

Keywords: boletes, porcini, flavor chemistry, metabolomics, GC-MS, ATR-FTIR, chemometrics, volatile compounds, amino acids, TCA cycle, molecular docking, CNN-LSTM

The team began by searching for cellular partners of vIRF3 in lymphatic endothelial cells using immunoprecipitation followed by mass spectrometry. Among the proteins that specifically co-purified with the viral factor was a polypeptide of roughly sixty kilodaltons corresponding to pyruvate kinase M. Although vIRF3 could bind both the PKM1 and PKM2 isoforms in pull-down assays, only PKM2 was expressed in lymphatic endothelial cells, so the investigators focused their attention on the vIRF3–PKM2 axis. Detailed binding experiments mapped the interaction to a short region of vIRF3 spanning amino acids 250 to 280. Deleting this segment produced a mutant viral protein, vIRF3-MT, that lost the ability to bind PKM2 while retaining its interactions with other known partners, including IRF7, HIF1α and HDAC5, making it a clean genetic tool for isolating the metabolic consequences of the interaction.

The biological significance of the binding became apparent when the researchers examined the oligomeric state of PKM2. This enzyme exists in two functionally distinct forms: a tetramer that acts as an active pyruvate kinase, channeling carbon from phosphoenolpyruvate into pyruvate and onward into the tricarboxylic acid cycle, and a nuclear dimer that functions as a transcriptional co-factor supporting aerobic glycolysis. When wild-type vIRF3 was expressed in lymphatic endothelial cells, cross-linking experiments showed a striking increase in PKM2 tetramerization, accompanied by elevated pyruvate kinase activity, higher intracellular acetyl coenzyme A levels and reduced lactate concentrations. The mutant viral protein, lacking the PKM2-binding region, produced none of these effects. Seahorse metabolic flux analysis reinforced the picture: cells expressing wild-type vIRF3 showed significantly increased oxygen consumption rates, including higher basal respiration, ATP production and maximal respiratory capacity, while their extracellular acidification rate, a proxy for glycolysis, declined.

To trace where the newly abundant acetyl-CoA came from, the team performed liquid chromatography–mass spectrometry metabolomics and isotope tracing with uniformly labeled carbon-13 glucose. In cells expressing wild-type vIRF3, pyruvate accumulated predominantly in the M+3 isotopologue form, a signature of enhanced PKM2 activity, and the labeled carbon flowed into M+1 and M+2 acetyl-CoA, which then fed the biosynthesis of citrate, α-ketoglutarate, succinate, fumarate and malate. Glutamate labeling patterns indicated that the cells were not relying on glutaminolysis to replenish the cycle, and measurements of fatty acid oxidation intermediates showed that this pathway was actually suppressed: carnitine accumulated while expression of carnitine palmitoyltransferase 1A and downstream β-oxidation intermediates fell. The evidence therefore pointed to enhanced pyruvate catabolism, rather than fatty acid oxidation or glutamine metabolism, as the principal source of the expanded acetyl-CoA pool.

Acetyl-CoA is not merely a fuel; it donates acetyl groups for the lysine acetylation of thousands of proteins, including transcription factors. Consistent with this, wild-type vIRF3 expression raised the global acetylation level of cellular proteins, and this increase depended on citrate exported from mitochondria and processed by ATP citrate lyase, since the ACLY inhibitor BMS-303141 abolished the effect. A human protein acetylation microarray then identified twenty-four proteins whose acetylation rose specifically in the presence of the vIRF3–PKM2 interaction. Among them, the investigators prioritized SMAD5, a transcriptional effector of TGFβ–BMP signaling with established roles in endothelial-to-mesenchymal transition, the process by which endothelial cells lose their identity and acquire invasive, mesenchymal characteristics.

Immunoprecipitation confirmed that SMAD5 acetylation was markedly increased in cells expressing wild-type vIRF3 but not the binding-defective mutant, and co-immunoprecipitation identified the acetyltransferase p300 as the enzyme responsible, since the p300 inhibitor A-485 reduced SMAD5 acetylation. The functional consequences were dramatic. Cells expressing wild-type vIRF3 adopted a spindle-shaped, mesenchymal morphology, downregulated the endothelial markers LYVE-1 and VE-cadherin, and upregulated mesenchymal markers including vimentin, fibronectin, N-cadherin and α-smooth muscle actin. Three-dimensional spheroid invasion assays in Matrigel and Boyden chamber migration assays demonstrated that these behaviors depended on SMAD5: silencing SMAD5 with short hairpin RNAs abolished both the invasive growth and the migration induced by vIRF3.

Critical controls established that this metabolic hijacking is separable from the viral life cycle itself. Using bacterial artificial chromosome-based recombination, the team constructed recombinant KSHV clones carrying either wild-type vIRF3, the Δ250-280 deletion mutant, or a revertant restoring the wild-type sequence. The mutant virus replicated normally, produced comparable infectious virions and expressed latent and lytic genes at levels indistinguishable from wild type. Yet when lymphatic endothelial cells were infected with these viruses, only wild-type and revertant infections raised pyruvate kinase activity and acetyl-CoA levels, drove spheroid invasion, and enabled colony formation in soft agar. The phenotypes were reproduced in primary human lymphatic endothelial cells, confirming that the metabolic reprogramming is a genuine consequence of KSHV infection rather than an artifact of immortalized cell lines.

The in vivo consequences were equally striking. In xenograft experiments with immunodeficient NCr-nu/nu mice, cells infected with wild-type or revertant KSHV formed tumors efficiently, whereas cells infected with the vIRF3-MT virus did not. Moreover, mice bearing wild-type-derived tumors developed secondary lesions in the stomach, spleen and liver that displayed hallmark histopathological features of Kaposi’s sarcoma, including extravasated erythrocytes, hemosiderin deposits and spindle-shaped cells positive for the viral latency antigen LANA, vIRF3, the endothelial marker CD31 and the lymphatic lineage factor PROX1. Human vimentin-positive cells at these sites traced back to the implanted infected endothelial cells. No secondary tumors appeared in mice injected with the PKM2-binding-defective virus, directly implicating the vIRF3–PKM2 interaction in disseminated visceral disease.

The study also delivers a potential therapeutic lead. Because amino acids 250 to 260 of vIRF3 were sufficient for PKM2 binding, the researchers designed a short vIRF3-derived peptide, termed VDP, fused to the HIV TAT transduction domain for intracellular delivery. VDP competed with vIRF3 for PKM2 binding, blocked vIRF3-induced PKM2 tetramerization and enzymatic activity, and lowered acetyl-CoA and ATP levels, while a binding-defective mutant peptide, mVDP, did none of these things. Structural modeling with AlphaFold-Multimer and molecular dynamics simulations showed VDP occupying the intersubunit interface of PKM2, and biolayer interferometry measured a dissociation constant of 1.28 micromolar, roughly twenty-nine-fold tighter than the mutant peptide. In chick embryo chorioallantoic membrane assays, TAT-VDP suppressed vIRF3-driven invasion into the endoderm layer, and in xenograft mice the peptide markedly inhibited tumor formation and regressed established tumors without substantial toxicity.

The authors caution that the vIRF3–PKM2–acetyl-CoA–SMAD5 axis still requires validation in patient-derived Kaposi’s sarcoma tissues, which have been difficult to obtain in adequately preserved form, and that their xenograft model does not distinguish true metastatic dissemination from other routes of systemic distribution. Even so, the work provides the most complete mechanistic account to date of how an oncogenic herpesvirus converts a host metabolic enzyme into an engine of tumor progression, linking acetyl-CoA flux through the TCA cycle to epigenetic modification of a developmental transcription factor. By demonstrating that a rationally designed viral peptide can reverse this process in living animals, the study positions PKM2 not merely as a metabolic marker but as an actionable target for treating disseminated Kaposi’s sarcoma.

Subject of Research: KSHV vIRF3–PKM2 interaction, acetyl-CoA metabolic reprogramming and SMAD5 acetylation in Kaposi's sarcoma progression

Article Title: KSHV vIRF3–PKM2 interaction induces SMAD5 acetylation, promoting Kaposi’s sarcoma progression

Article References: Kim, Y. J., Lim, J., Lee, J. J., Kumar, A., Kannappan, S., Zhang, J., Kim, S., Kim, H.-J., Kim, K. K., Toth, Z., Eoh, H., Choi, K.-C., & Lee, H.-R. (2026). KSHV vIRF3–PKM2 interaction induces SMAD5 acetylation, promoting Kaposi’s sarcoma progression. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01849-2

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01849-2

Keywords: KSHV, Kaposi's sarcoma, vIRF3, PKM2, acetyl-CoA, SMAD5 acetylation, lymphatic endothelial cells, endothelial-to-mesenchymal transition, metabolic reprogramming, p300, TCA cycle, therapeutic peptide

The centerpiece of the new work is the pyruvate dehydrogenase complex, or PDHc, a multi-enzyme assembly that sits at one of the most consequential crossroads in cellular metabolism. Glycolysis in the cytoplasm converts glucose into pyruvate, and the fate of that pyruvate determines which metabolic program the cell will run. When PDHc is active, it catalyzes the oxidative decarboxylation of pyruvate into acetyl-coenzyme A, which then feeds the tricarboxylic acid cycle, or TCA cycle, inside mitochondria, driving the production of NADH and FADH2 that power oxidative phosphorylation. When PDHc is inhibited, pyruvate is instead reduced to lactate, the TCA cycle slows, and the cell becomes dependent on glucose fermentation and on the diversion of glycolytic intermediates into biosynthetic pathways that support rapid proliferation. PDHc activity is therefore a metabolic master switch, and its regulation is a matter of life and death for a growing tumor.

The canonical off switch for PDHc is phosphorylation. Pyruvate dehydrogenase kinase 1, or PDK1, attaches phosphate groups to the E1 alpha subunit of the complex, PDHE1α, and this inhibitory mark suppresses the enzyme’s decarboxylase activity. Pharmaceutical efforts to reverse this blockade have centered on dichloroacetate, or DCA, a small molecule that inhibits PDK enzymes and thereby restores PDHc flux. What has remained less clear is how tumor cells recruit and amplify PDK1 activity in the first place, and whether noncoding RNAs, a class of regulatory molecules long suspected of shaping cancer metabolism, participate directly in this process. The new study provides a striking answer to both questions.

The researchers began with an observation that challenges the traditional division of labor between proteins and RNAs: PDHE1α, an enzyme long considered a purely metabolic protein, can bind RNA. Among the transcripts that associate with it is SNHG15, a long noncoding RNA that has previously been implicated in the progression of several cancers but whose metabolic functions were poorly defined. This RNA-protein interaction suggested that a noncoding transcript might physically insert itself into the machinery that governs mitochondrial fuel oxidation, a possibility the team pursued through a series of mechanistic experiments in hepatocellular carcinoma cells.

The mechanism that emerged is a scaffold model of metabolic control. According to the authors’ analysis, SNHG15 facilitates the interaction between phosphoglycerate kinase 1, PGK1, a glycolytic enzyme, and PDK1, and it simultaneously promotes the association between PDK1 and its substrate, PDHE1α. In effect, the RNA acts as a molecular matchmaker, bringing the kinase into proximity both with its upstream activator and with the enzyme it phosphorylates. The consequence is increased phosphorylation of PDK1 itself and of PDHE1α, which suppresses the catalytic activity of the pyruvate dehydrogenase complex. With PDHc throttled back, pyruvate oxidation into the TCA cycle declines, glycolysis accelerates, and lactate production rises, the classic biochemical signature of the Warburg phenotype.

This reprogramming is not merely a correlative curiosity; the study connects it directly to malignant behavior. In cell models, SNHG15-driven suppression of the TCA cycle promoted the glycolytic flux that fuels hepatocellular carcinoma progression. The team then extended the findings into xenograft models, in which tumor cells are implanted into experimental animals. Tumors with elevated SNHG15 grew more aggressively, and biochemical analysis of those tumors revealed increased lactate production alongside heightened phosphorylation of both PDK1 and PDHE1α, confirming that the RNA-protein phosphorylation axis operates in living tumors and not only in culture dishes.

Perhaps the most therapeutically compelling result came when the researchers administered dichloroacetate to the xenograft-bearing animals. DCA, which inhibits pyruvate dehydrogenase kinases and thereby releases the brake on PDHc, significantly reversed the oncogenic effects of SNHG15. Tumor growth was blunted, and the metabolic markers of the Warburg state receded. This pharmacological rescue is important because it demonstrates causality: if blocking PDK1 activity negates the tumor-promoting effects of the RNA, then the RNA’s oncogenic power flows substantially through that kinase, and the PGK1-PDK1-PDHE1α axis becomes a defined, druggable vulnerability rather than a loose correlation.

The study also broadens the conceptual repertoire of long noncoding RNA biology. LncRNAs have typically been cast as regulators of gene expression, modulating transcription, chromatin state, or messenger RNA stability. Here, SNHG15 acts instead at the level of enzyme activity, functioning post-translationally by organizing protein-protein interactions. The finding that PDHE1α itself is an RNA-binding protein adds to a growing recognition that core metabolic enzymes moonlight as participants in RNA-based regulatory networks, blurring the boundary between the genome’s informational layer and its metabolic machinery. In this view, noncoding RNAs can serve as intracellular scaffolds that rewire enzyme kinetics on demand, offering tumors a rapid and reversible means of adapting their metabolism to the demands of proliferation.

For hepatocellular carcinoma specifically, the clinical implications are worth weighing carefully. Liver cancer is frequently diagnosed at advanced stages and remains among the leading causes of cancer mortality worldwide, and metabolic vulnerabilities have long been proposed as therapeutic entry points. The SNHG15-PDK1-PDHE1α pathway offers several potential intervention surfaces: targeting the RNA itself with antisense or degrading strategies, disrupting its interaction with PDHE1α or PGK1, or inhibiting PDK1 pharmacologically, an approach already tested clinically with DCA in various contexts. The authors position the PGK1-PDK1-PDHE1α axis as a candidate target for clinical intervention, and the xenograft data with DCA provide an early proof of principle, though the gap between animal models and human therapy remains substantial and will require validation in patient-derived systems and ultimately clinical trials.

As with any study, important questions remain open. The precise structural basis of the SNHG15-PDHE1α interaction, the determinants of SNHG15 overexpression in liver tumors, and the relationship between this metabolic scaffold function and any other roles the RNA may play in HCC cells all await further definition. The work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Shandong Province and related institutional funds, and the authors declare no competing interests. What the study establishes, however, is a clear mechanistic narrative: a long noncoding RNA can hijack a phosphorylation cascade at the glycolysis-mitochondria junction, silence the TCA cycle, and push liver cancer cells into the fermentative metabolism on which their growth depends, and that same cascade can be chemically disarmed. In doing so, it adds a new layer to the metabolic playbook of hepatocellular carcinoma and offers researchers a concrete molecular handle on one of cancer’s oldest and most stubborn adaptations.

Subject of Research: Metabolic reprogramming of hepatocellular carcinoma by the lncRNA SNHG15 through PDK1 and PDHE1α phosphorylation

Article Title: SNHG15 inhibits the tricarboxylic acid cycle and promotes HCC progression by facilitating the phosphorylation of PDK1 and PDHE1α

Article References: Chen, H., Wang, Y., Chong, W., Wang, X., Wang, L., Zhang, J., Zhao, X., & Wang, C. (2026). SNHG15 inhibits the tricarboxylic acid cycle and promotes HCC progression by facilitating the phosphorylation of PDK1 and PDHE1α. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03380-9

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03380-9

Keywords: hepatocellular carcinoma, SNHG15, long noncoding RNA, pyruvate dehydrogenase complex, PDK1, PDHE1α, PGK1, TCA cycle, glycolysis, Warburg effect, dichloroacetate, cancer metabolism

MASLD, the modern name for what was long called non-alcoholic fatty liver disease, is defined by the accumulation of fat in liver cells in the presence of overweight, insulin resistance or other cardiometabolic risk factors. It affects an estimated three in ten adults globally and can progress to inflammation, fibrosis and cirrhosis, yet there are no approved pharmacological therapies for the majority of patients, and management rests on diet, exercise and weight loss. Because the disease develops silently over years, researchers have increasingly turned to metabolomics, the systematic measurement of small molecules in blood, to find early warning signs and, ideally, modifiable targets. Circulating amino acids have repeatedly surfaced in such studies, but individual metabolites fluctuate with meals, genetics and physiology, making it difficult to know which combinations actually matter for disease trajectories.

The new study took a pattern-based approach. Rather than asking whether any single amino acid predicts liver fat, the team used principal component analysis, a statistical technique that compresses many correlated variables into a small number of composite scores, to derive patterns from targeted metabolomic measurements of serum essential amino acids. Essential amino acids are those the human body cannot synthesize and must obtain from food: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Because they come from the diet yet are heavily processed by the liver and by gut microbes, their circulating levels sit at a biological crossroads between what a person eats, how their metabolism handles it, and how their liver is functioning.

The discovery cohort comprised 867 participants of the Guangzhou Nutrition and Health Study who had targeted metabolomics available at baseline and at follow-up visits two through four. MASLD status was assessed across follow-ups one to four, deliberately excluding baseline so that the analysis could capture new disease onset rather than prevalent cases. From metabolite levels averaged across visits, the researchers derived an incidence-oriented essential amino acid pattern score. Participants with a pattern characterized by relatively higher methionine and threonine and relatively lower valine, leucine and isoleucine had a markedly lower risk of developing MASLD: the standardized hazard ratio was 0.61, with a 95 percent confidence interval of 0.51 to 0.73. In other words, across the distribution of the pattern score, those at the favorable end faced roughly 39 percent lower hazard of incident disease than those at the unfavorable end.

Crucially, the same pattern told a story about recovery. Among participants who had MASLD during the study, a recovery-oriented pattern score was associated with significantly greater odds of the disease resolving, with a standardized estimate of 2.06 and a 95 percent confidence interval of 1.67 to 2.53. The team also constructed a combined pattern score and a recovery-derived score, and the associations held. To guard against the possibility that the discovery result was a statistical fluke of one cohort, the researchers validated the pattern in 1,623 additional participants from the same Guangzhou study and then externally in 481,982 participants of the UK Biobank, a vast biomedical database of British adults. The direction and magnitude of the associations were consistent across these independent populations, lending considerable weight to the conclusion that the amino acid signature is not an artifact of a single Chinese cohort.

What might explain the biology? The investigators identified thirteen metabolites related to the favorable essential amino acid pattern that appeared to partly mediate, or statistically account for, the association between the pattern and MASLD outcomes. Among them were key intermediates of the tricarboxylic acid cycle, the Krebs cycle that sits at the heart of cellular energy metabolism: pyruvic acid, isocitric acid and oxoglutaric acid. This is mechanistically coherent. Branched-chain amino acids, which are catabolized heavily in muscle and liver, feed carbon into central energy metabolism, and chronically elevated circulating branched-chain amino acids have long been associated with insulin resistance and hepatic fat accumulation. Methionine, by contrast, is central to one-carbon metabolism and the synthesis of S-adenosylmethionine, a molecule involved in phosphatidylcholine production and very-low-density lipoprotein export from the liver, while threonine is a substrate for glycine and serine synthesis and for mucin production in the gut. A pattern favoring methionine and threonine over branched-chain amino acids may therefore reflect a metabolic state in which hepatic fat handling and mitochondrial energy flux are better balanced.

The mediation analysis, conducted with false discovery rate control and a significance threshold of P less than 0.05, suggests that the TCA cycle intermediates and related metabolites carry part, though not all, of the association. The authors are careful on this point: the metabolites may partly account for the amino acid pattern’s relationship with MASLD, but the data cannot prove that manipulating amino acid levels would directly change liver fat. Serum amino acids are themselves influenced by diet, insulin action, kidney function and the gut microbiome, so the pattern may be best understood as a circulating metabolic signature, an integrated readout of metabolic health, rather than a simple causal lever.

That said, the study did find that the favorable pattern travels with modifiable behavior. Using food frequency questionnaires and validated indices, the researchers showed that a healthy diet and lifestyle were positively associated with the beneficial essential amino acid pattern. Higher scores on measures such as the Alternate Mediterranean Diet Score, the Dietary Approaches to Stop Hypertension score, the healthful plant-based diet index and overall dietary diversity were linked to the pattern characterized by higher methionine and threonine and lower branched-chain amino acids. This is an important bridge from biomarker to action: it suggests that the kinds of diets already recommended for cardiometabolic health, rich in plant foods, whole grains and diverse protein sources, are associated with the amino acid profile that tracks with lower MASLD risk and better recovery.

The implications for prevention are tantalizing but must be framed with appropriate caution. Branched-chain amino acids are abundant in animal protein and whey supplements, and their elevation in obesity is thought to reflect both intake and impaired catabolism. The study does not suggest that people should avoid protein or seek out methionine and threonine supplements; indeed, the authors explicitly state that the pattern’s clinical utility requires further validation before it can inform practice. What the work does provide is a candidate biomarker that could, with future research, help stratify risk, monitor response to lifestyle intervention, and guide the design of nutritional trials. A blood test that captures an integrated amino acid signature could eventually complement ultrasound and liver enzyme panels in identifying who is drifting toward fatty liver years before disease becomes detectable by conventional means.

The scale and design of the study set it apart from much of the prior metabolomics literature. Twelve years of follow-up across five visits in the Guangzhou cohort allowed the researchers to separate incidence from recovery, two outcomes that many cross-sectional studies conflate. The external validation in the UK Biobank, spanning a different ancestry, diet and health system, addresses one of the most persistent weaknesses of metabolomic biomarker research, which is overfitting to the population in which a signature was discovered. Funded by the National Natural Science Foundation of China and the 5010 Program for Clinical Research of Sun Yat-sen University, the work exemplifies a growing trend of rigorous, pattern-level metabolomic epidemiology. As MASLD continues its rise in parallel with obesity and diabetes worldwide, the search for early, modifiable metabolic signatures has become a public health priority. This study’s essential amino acid pattern, anchored in the biochemistry of the Krebs cycle and associated with healthy diets, offers a promising thread to pull, and future intervention studies will determine whether shifting this signature through diet and lifestyle can genuinely bend the curve of the global fatty liver epidemic.

Subject of Research: Serum essential amino acid patterns and their association with incidence and recovery of metabolic dysfunction–associated steatotic liver disease

Article Title: Identifying serum essential amino acid patterns protective against the incidence and conducive to the recovery of metabolic dysfunction–associated steatotic liver disease: a prospective cohort study

Article References: Lu, Z., Zhou, K., Cheng, M., Mamuti, R., Zhou, F., Huang, F., Xi, Y., Deng, K., Xu, L., Wang, J., Xie, G., & Chen, Y.-M. (2026). Identifying serum essential amino acid patterns protective against the incidence and conducive to the recovery of metabolic dysfunction–associated steatotic liver disease: a prospective cohort study. BMC Medicine. https://doi.org/10.1186/s12916-026-05201-3

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05201-3

Keywords: MASLD, essential amino acids, branched-chain amino acids, methionine, threonine, metabolomics, TCA cycle, prospective cohort, UK Biobank, fatty liver disease, nutrition, Guangzhou Nutrition and Health Study

The team began with a deceptively basic question: if a cell has a fixed total amount of enzyme to spend on a linear pathway, how should it divide that investment among the individual reaction steps to achieve the highest possible flux? Starting from a chain of first-order reactions, and then extending the analysis to zero-order and full reversible Michaelis–Menten kinetics, the researchers used Lagrange multiplier methods to derive an explicit optimality condition. At maximal flux efficiency, the equilibrium constant of each reaction must equal what they call the catalytic-abundance quotient, or CAQ, of the adjacent reaction pair. In other words, thermodynamics and enzyme economics become locked together: reactions with larger equilibrium constants, which are less likely to stall near equilibrium, should receive proportionally greater enzyme investment.

What makes this K-CAQ relationship remarkable is its simplicity. Earlier theoretical work on metabolic control analysis, dating back to the 1970s, established that flux control coefficients should be proportional to enzyme abundances at optimal efficiency, but those classical results were formulated long before high-throughput omics data existed and were difficult to test directly. For realistic Michaelis–Menten kinetics, previous optimization problems became highly nonlinear with no analytical solution. The new derivation cuts through that complexity, producing a closed-form relationship that can be checked against real data, and it survives numerical simulation of ten-reaction pathways across thousands of randomly sampled parameter sets, where log-transformed K and CAQ values showed near-perfect agreement at the optimum regardless of enzyme saturation levels.

To test the theory against biology, the researchers assembled an unusually rich dataset spanning three evolutionarily distant organisms: human, budding yeast, and the bacterium Escherichia coli. They drew on quantitative proteomics from 378 human cancer cell lines in the Cancer Cell Line Encyclopedia, transcriptomics from more than 5,000 tumor and normal tissue samples in The Cancer Genome Atlas, and absolute protein abundance datasets for yeast and E. coli. Equilibrium constants were computed from standard Gibbs free energy changes and adjusted for intracellular cofactor concentrations such as ATP, ADP, and the NAD redox pairs, while catalytic efficiencies were estimated from kcat and Km values predicted by deep learning tools together with measured metabolite concentrations. Isozymes and cofactor dependencies, two complications that usually derail such analyses, were handled with generalized formulations of the K-CAQ equation.

The first encouraging result was that enzyme allocation itself is strikingly conserved. Across human cancer cell lines from wildly different tissues of origin, the relative abundance of metabolic enzymes showed median pairwise Spearman correlations exceeding 0.8 at both protein and transcript levels, and glycolytic enzyme proportions were similarly preserved. When the team compared the measured CAQ values to equilibrium constants for glycolysis in all three species, they found a moderate but consistent coupling, quantified by a new metric they call the Efficiency Optimality Index, the root mean squared error between log K and log CAQ. Median EOI values hovered around 2.5 in human samples, with similar patterns in yeast and bacteria. Flux efficiency maximization, it appeared, is one real objective shaping pathway design, but not the only one.

The deviations from the ideal relationship turned out to be anything but random. The largest mismatches repeatedly occurred at the same reaction pairs across species: the steps involving glucose transport, hexokinase, and phosphofructokinase in human and yeast glycolysis, and the glucose phosphotransferase step in E. coli. These are precisely the reactions long recognized as the master control points of glycolytic flux. At these steps, the measured CAQ was consistently smaller than K, meaning the enzymes were expressed at lower levels than pure efficiency maximization would predict. The researchers realized that this underinvestment is not wasteful at all. In metabolic control analysis, reducing the abundance of an enzyme increases its flux control coefficient, its leverage over the total pathway flux. By starving key control enzymes of resources, the cell concentrates regulation into a handful of sensitive, tunable steps.

This insight crystallized into a formal trade-off between two competing objectives: flux efficiency, the flux achieved per unit of total enzyme, and control efficiency, defined as the standard deviation of flux control coefficients across the pathway. Using an epsilon-constraint algorithm, the team computed the Pareto front that balances these two goals, tracing the set of enzyme allocation profiles where neither objective can be improved without sacrificing the other. When they matched physiological CAQ profiles from proteomics onto this front, the agreement was striking. The Pareto front correctly predicted the direction of deviation between K and CAQ for more than eighty percent of reaction pairs in human glycolysis, and the CAQ-matched Pareto solution correlated strongly with experimental values in all three species, with Pearson correlations between 0.62 and 0.71. The same framework extended successfully to the E. coli TCA cycle, where deviations clustered around the alpha-ketoglutarate dehydrogenase step, a known control point of that pathway.

Perhaps the most convincing validation came from metabolite concentrations. When the researchers simulated glycolysis using enzyme profiles that maximize flux efficiency alone, the predicted metabolite levels were systematically far too high and matched experiments poorly, with a root mean squared error around four orders of magnitude in log space. Enzyme profiles from the Pareto front, however, reproduced measured metabolite concentrations remarkably well, achieving correlations of 0.67 in human cells, 0.90 in yeast, and 0.69 in E. coli. Crucially, the team also showed that this agreement was not an artifact of calibrating the Pareto solution with proteomics: when they instead selected solutions using independent metabolomics data, the predictions still matched proteomics-derived CAQ profiles, with permutation tests confirming that real enzyme allocations sit significantly closer to the Pareto front than randomly shuffled ones.

Finally, the study asked what determines where along the Pareto front a given cell chooses to operate. Analyzing eight cancer types in TCGA, the researchers found that lower EOI values, indicating tighter optimization of glycolytic efficiency, were consistently associated with activation of oncogenic signaling pathways, suggesting that aggressive tumors do not merely crank up glycolysis but actively reorganize it for maximum efficiency. Conversely, higher EOI correlated with enhanced expression of ribosomal and oxidative phosphorylation genes, hinting at competition between glycolytic efficiency and other energy-consuming programs. A third pattern was perhaps the most evocative: across 16 of 19 sample groups, cells that devoted a smaller fraction of their proteome to glycolytic enzymes showed stronger efficiency optimization. Scarcity, it seems, drives cells toward the same rational economizing that shapes human decision-making under budget constraints.

The implications reach well beyond basic biochemistry. Because the K-CAQ relationship provides an explicit, testable target for pathway design, it offers metabolic engineers a rational blueprint for building synthetic pathways that avoid the chronically low efficiencies that plague engineered metabolism today. Conceptually, the work reframes metabolic regulation as a multi-objective optimization problem, echoing design principles seen elsewhere in biology, from master regulators in development to command neurons in animal behavior, where concentrating control into a few nodes simplifies the management of a complex network. The authors caution that their framework does not capture every metabolic objective, including robustness to environmental fluctuations and metabolite load minimization, and a complete picture will require higher-dimensional Pareto fronts across genome-scale networks. But the core message stands: cells are not simply maximizing throughput, nor simply maximizing controllability, but navigating a quantifiable frontier between the two, and that frontier can now be read directly from omics data.

Subject of Research: Optimality principles governing enzyme allocation in metabolic pathways

Article Title: Trade-off between flux efficiency and metabolic control shapes enzyme allocation

Article References: Sun, K., Zheng, W., Fan, W., Ding, C., Huang, D., & Dai, Z. (2026). Trade-off between flux efficiency and metabolic control shapes enzyme allocation. Molecular Systems Biology. https://doi.org/10.1038/s44320-026-00250-5

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00250-5

Keywords: metabolism, enzyme allocation, flux efficiency, metabolic control analysis, glycolysis, TCA cycle, Pareto optimality, thermodynamics, proteomics, systems biology, cancer metabolism, metabolic engineering

T. brucei leads a double life, cycling between the bloodstream of mammals and the gut of the tsetse fly. Within the mammalian host, the parasite exists mainly in two forms: the long slender form, which divides rapidly and drives parasitaemia upward, and the short stumpy form, a non-dividing stage produced through a quorum-sensing mechanism once parasite density climbs. The stumpy form is the parasite’s ticket to the next stage of its life cycle, primed to differentiate into procyclic forms once it reaches the fly. Yet stumpy cells are also fragile. Earlier work showed they survive only around four days in the bloodstream, and during the remission of the first parasitaemic peak in mice they disappear far faster than their natural turnover alone could explain. Something else, the researchers suspected, was accelerating their demise.

The team’s first clue came from body temperature. In C57BL/6J mice infected with pleomorphic T. brucei, parasitaemia first became detectable around three days post-infection, and by day four the slender forms had begun differentiating into stumpy cells just as fever set in. Both parasite load and body temperature peaked on days four and five, when stumpy forms made up nearly three-quarters of the population. Parasitaemia then collapsed to undetectable levels by day seven, coinciding with the return of body temperature to baseline. A Pearson correlation analysis confirmed a strong positive relationship between parasitaemia and temperature during the first week of infection, with a correlation coefficient of 0.678. A multiple linear regression model, which explained 67.54 percent of the variance in late-phase parasite levels, singled out the temperature window spanning days three to five as a significant predictor of subsequent parasite decline.

To test whether heat itself could kill stumpy cells, the researchers purified them from infected mice and cultured them at different temperatures. At 27 degrees Celsius, the temperature of the tsetse fly, the cells survived and even began differentiating into procyclic forms. At 37 degrees, normal mammalian body temperature, they underwent their expected natural turnover over roughly three to four days. But at 39 degrees, a fever temperature previously recorded in infected mice, mortality climbed steeply. Notably, long slender forms tolerated prolonged heat exposure far better; only the stumpy cells declined sharply within the first 48 hours. Fever, the results suggest, places a disproportionate burden on the very stage of the parasite that is already winding down.

The interplay with antibodies proved equally revealing. Plasma from mice at 21 days post-infection, rich in effective antibodies, suppressed stumpy cells in culture but could not eliminate them completely, unlike its effect on slender forms. Plasma from mice at day six, when the first peak collapses, showed no killing activity against either form. Yet when elevated temperature and day-21 plasma were combined, more than 99.5 percent of stumpy cells were eradicated within 24 hours, while either treatment alone left 15 to 18 percent alive. This synergy indicates that the well-documented IgM and complement-mediated clearance of the first parasitaemic peak is only part of the story. The parasite’s own heat sensitivity, amplified by fever, appears to be an underappreciated partner in that dramatic remission.

What happens inside a heat-stressed stumpy cell? The researchers found that apoptosis-like events, detected through phosphatidylserine exposure, rose from almost nothing at 27 degrees to 3.72 percent after 24 hours at 37 degrees and 30.63 percent at 39 degrees. Slender forms showed essentially no such events at any temperature. Gene expression analysis pointed to the mitochondrion as the driver: Metacasp-3, a mitochondrial-associated apoptosis gene, was upregulated roughly twofold at 37 degrees. Fluorescence imaging of mitochondria stained with MitoTracker revealed progressive damage, with punctate dye aggregation appearing in about 43 percent of cells after 24 hours at 37 degrees and over 95 percent after the same period at 39 degrees. Transmission electron microscopy confirmed the structural toll, showing fenestrated mitochondrial membranes and multivesicular structures suggestive of a stress-induced degradative pathway resembling autophagy.

Mitochondrial dysfunction went hand in hand with oxidative stress. Using MitoSOX staining, the team measured mitochondrial reactive oxygen species accumulating in stumpy cells exposed to heat: 15.30 percent of cells showed oxidative stress after 24 hours at 37 degrees, rising to 44.58 percent at 39 degrees, while cells kept at 27 degrees remained largely unaffected. The reactive oxygen species co-localized with the damaged mitochondria, reinforcing the link between heat, mitochondrial injury, and cell death. Mitochondrial membrane potential, a key indicator of mitochondrial health, collapsed in parallel, falling to 51.36 percent of baseline at 37 degrees and just 19.38 percent at 39 degrees. Slender forms, by contrast, showed neither mitochondrial oxidative stress nor membrane potential loss under the same conditions.

Untargeted metabolomics added a metabolic dimension to the picture. Comparing stumpy cells incubated for 12 hours at 37 versus 39 degrees, the researchers detected 306 significantly altered metabolites among more than 22,000 measured. The most striking change was a sixfold accumulation of succinate at fever temperature, alongside elevated glucose-6-phosphate and 3-phosphoglycerate, pointing to disrupted energy production through glycolysis and the TCA cycle. The team attributes the succinate surge to mitochondrial fumarate reductase, an enzyme known to generate reactive oxygen species and highly expressed in stumpy cells. Lipid metabolism was also disturbed: myristic acid, a key component of the parasite’s surface GPI anchors, accumulated at 39 degrees, while carnitine, needed for fatty acid degradation, dropped significantly, suggesting the cells could neither properly remodel nor dispose of their lipids under febrile stress.

The findings carry broader implications for how trypanosome infections unfold. Stumpy cells lack complexes III and IV of the electron transport chain and maintain their membrane potential through glycolysis-derived ATP and a reversed ATP synthase, a precarious arrangement the authors describe as dancing on a knife-edge. This metabolic mismatch between a partially activated TCA cycle and a limited antioxidant arsenal, including lower levels of iron superoxide dismutase than in slender forms, may be an evolutionary trade-off that pre-adapts the parasite for the insect gut at the cost of vulnerability to mammalian fever. It may also explain why trypanosomes take refuge in the cooler, peripheral tissues of the skin and adipose tissue, and why livestock species with naturally higher baseline body temperatures often show low parasitaemia yet remain reservoirs for transmission.

The authors caution that they were unable to create a fever-suppressed mouse model to prove causation directly, though earlier veterinary studies found that anti-inflammatory drugs raised parasitaemia in infected animals, indirectly supporting the fever-clearance hypothesis. They also note that natural infections initiated by tsetse bites produce lower first peaks than experimental injections, so fever’s role there may be more modest, though still relevant before specific antibodies appear. Because fever is among the most common clinical signs in human patients, and because stumpy cells resist antibody-mediated elimination better than slender forms do, the study proposes that temperature-driven clearance complements immunity throughout infection. Understanding the molecular basis of this thermo-sensitivity, the researchers conclude, could open new avenues for controlling a disease that still threatens millions across sub-Saharan Africa.

Subject of Research: Heat-induced degeneration of short stumpy Trypanosoma brucei forms and the role of fever in clearing the first parasitaemic peak

Article Title: Thermo-related degeneration of stumpy forms of Trypanosoma brucei, the pathogen of African sleeping sickness

Article References: Luo, J.-Y., Wang, J.-F., Yang, J., Zhang, P., Hide, G., Lai, D.-H., & Lun, Z.-R. (2025). Thermo-related degeneration of stumpy forms of Trypanosoma brucei, the pathogen of African sleeping sickness. Advanced Biotechnology, 3(4), Article 28. https://doi.org/10.1007/s44307-025-00081-9

Image Credits: AI Generated

DOI: 10.1007/s44307-025-00081-9

Keywords: Trypanosoma brucei, sleeping sickness, short stumpy form, fever, mitochondrial damage, oxidative stress, apoptosis-like cell death, metabolomics, glycolysis, TCA cycle, parasitaemia, tsetse fly